companydirectorylist.com  Global Business Directories and Company Directories
Search Business,Company,Industry :


Country Lists
USA Company Directories
Canada Business Lists
Australia Business Directories
France Company Lists
Italy Company Lists
Spain Company Directories
Switzerland Business Lists
Austria Company Directories
Belgium Business Directories
Hong Kong Company Lists
China Business Lists
Taiwan Company Lists
United Arab Emirates Company Directories


Industry Catalogs
USA Industry Directories












Company Directories & Business Directories

cepi

nogent sur marne 94130 - FR-France

Company Name:
Corporate Name:
cepi
Company Title:  
Company Description:  
Keywords to Search:  
Company Address: 46 rue agnes soral,nogent sur marne 94130 - FR,,France 
ZIP Code:
Postal Code:
 
Telephone Number:  
Fax Number:  
Website:
 
Email:
 
Number of Employees:
 
Sales Amount:
 
Credit History:
Credit Report:
 
Contact Person:
 
Remove my name



copy and paste this google map to your website or blog!

Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples:
WordPress Example, Blogger Example)









Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer

(Any information to deal,buy, sell, quote for products or service)

Your Subject:
Your Comment or Review:
Security Code:



Previous company profile:
centreville production
centrinfo-actidev conseil
centuryfrance
Next company profile:
cepi
cepovett sa
cepovett sa










Company News:
  • Home page | CEPI
    CEPI is bolstering global manufacturing capacity in underserved regions and harnessing innovative technologies to improve the speed, scale and access of vaccine manufacturing in response to epidemic and pandemic threats
  • About CEPI | CEPI
    CEPI leverages its unique position within the global health and R D ecosystems, building on its proven track record of bringing together public-sector, private-sector and academic partners to accelerate the development of vaccines against emerging viral threats
  • Our portfolio - CEPI
    Our interactive portfolio provides information on each of the vaccine candidates that CEPI has invested in as well as our Centralised Lab Network, Preclinical Models and Vaccine Manufacturing Network partners
  • News - CEPI
    Keep up-to-date on the latest announcements and updates from CEPI and our global partners
  • Calls for Proposals - CEPI
    If you would like to get a broader understanding of a CEPI Call for Proposal and or see if your idea, project, technology, or approach meets our suitability and eligibility requirements, ahead of filling out your application or getting involved with CEPI, we can organise a “CEPI Tech Talk”
  • CEPI 2. 0 and the 100 Days Mission
    CEPI’s 2022-2026 strategy, known as CEPI 2 0, is helping to Prepare, Transform, and Connect the world so that it can respond to the next Disease X by accelerating the development of safe, effective, globally accessible vaccines in as little as 100 days
  • Why we exist - CEPI
    CEPI was launched at Davos in 2017 as the result of a consensus that a coordinated, international, and intergovernmental plan was needed to develop and deploy new vaccines to prevent future epidemics
  • CEPI Monitoring and Evaluation Framework
    This CEPI Monitoring and Evaluation (M E) Framework is intended to support implementation of CEPI’s strategy and programme document for the next business cycle (2022-2026) 1 Grounded in CEPI’s theory of change and associated key performance indicators (KPIs) (see Annex 2),
  • Bill Melinda Gates Foundation and Wellcome pledge $300 million . . . - CEPI
    The only public sector funder of R D, CEPI has leveraged its investments to enable equitable access to vaccines, and COVAX—co-led by CEPI—has legally binding commitments in place to access up to 3 billion doses of CEPI-funded COVID-19 vaccines for equitable distribution
  • Call for Proposals Focus Area 1: Innovative vaccine platforms . . . - CEPI
    CEPI invites proposals to advance vaccine platforms through Phase I proof of concept Developers with very early-stage technologies can apply for an Exploratory Award of up to US $1M over a




Business Directories,Company Directories
Business Directories,Company Directories copyright ©2005-2012 
disclaimer